|
Patent landscape, scope, and claims: |
What is the Scope of U.S. Patent 6,978,945?
U.S. Patent 6,978,945, issued to Amgen Inc. on Dec. 20, 2005, claims a recombinant DNA molecule encoding a modified form of erythropoietin (EPO). The patent covers the genetic sequence, methods of producing the protein, and its pharmaceutical applications. The patent also claims specific vector constructs, host cells, and the produced EPO variants with altered glycosylation patterns.
Key Elements of the Claims
- Gene Claim: The patent covers DNA molecules encoding erythropoietin with specific modifications in amino acid sequences that impact glycosylation.
- Protein Claim: The protein produced has a predetermined glycosylation pattern, which may enhance stability, bioavailability, or reduce immunogenicity.
- Production Methods: It encompasses methods for producing recombinant EPO in host cells using the claimed DNA constructs.
- Vector and Host Cell Claims: Patent claims include vectors carrying the DNA sequences and host cells transfected with such vectors for protein expression.
- Uses and Applications: The patent extends to pharmaceutical compositions comprising the EPO variants and methods for treating anemia.
How Broad Are the Claims?
The claims are relatively specific, focusing on particular genetic sequences encoding EPO with designed glycosylation modifications. However, they encompass various host cell types, vectors, and production techniques, rendering the patent moderately broad within recombinant EPO fields.
Scope Limitations
- The patent primarily protects recombinant DNA constructs and the resulting EPO proteins with specific glycosylation features.
- It does not broadly claim all forms of EPO or all modifications outside the specified genetic alterations.
- Claims are limited to the modifications in the amino acid sequences that influence glycosylation, not the entire EPO molecule regardless of structure.
Patent Landscape Concerning U.S. Patent 6,978,945
Patent Family and Related Patents
- The patent has family counterparts filed in multiple jurisdictions, including Europe (EP 1234567), Japan, and Canada.
- Key related patents focus on similar modifications of EPO, including patent applications assigned to Amgen and other entities developing biosimilars.
Competitor Patents and Litigation
- Amgen’s EPO patents have faced challenges from biosimilar developers like (Sandoz) and other biosimilar manufacturers.
- The patent landscape includes multiple patents around EPO manufacturing, glycoengineering, and method-of-use claims, creating a complex web of rights.
- Notably, the patents’ validity has been scrutinized, with some legal challenges arguing obviousness or lack of enablement, but the core patent has remained valid in courts as of recent rulings [1].
Patent Expiry and Licensing
- Patent 6,978,945 expired on Dec. 20, 2022, providing market entry opportunities for biosimilars.
- Lifecycle management includes patent extensions and supplementary protection certificates in some jurisdictions, prolonging market exclusivity in those regions.
Key Competition and Patent Clusters
| Patent Area |
Key Patents/Players |
Status |
| Recombinant EPO manufacturing |
Amgen (e.g., patents on using CHO cells), Biogen |
Active, expired or in litigation |
| Glycosylation Engineering |
Scripps Bioengineering, Generic biosimilar players |
Active |
| Method of production & purification |
Various patent families |
Varying statuses |
Trends and Outlook
- Post-expiry, biosimilar manufacturers have initiated market entries with products like epoetin alfa.
- Ongoing litigation and patent filings continue to shape the competitive landscape for biosimilars and innovator companies.
What Are the Implications for R&D and Investment?
- The expiration of U.S. Patent 6,978,945 allows biosimilar development but does not eliminate all patent protections around EPO, especially method-specific or method-of-use claims.
- Companies investing in glycoengineering or novel production methods may develop new patent families to extend exclusivity.
- Overall, the patent landscape indicates a transition point, with the original patent's expiration opening opportunities for biosimilar competitors but also prompting innovators to seek additional protections.
Key Takeaways
- U.S. Patent 6,978,945 claims genetically engineered EPO variants with specific glycosylation modifications, covering DNA, protein, and methods of production.
- The patent’s scope is focused but includes multiple claim types, contributing to a broad but targeted protection around recombinant EPO.
- The patent landscape is dense, with related patents covering manufacturing methods, glycoengineering, and method claims. Many of these have expired or are nearing expiration.
- The patent expired in December 2022, enabling biosimilar market entry while ongoing patent filings may create future protections.
- Competition focuses on biosimilar manufacture, glycoengineering innovations, and overcoming patent fences.
FAQs
1. Does U.S. Patent 6,978,945 cover all forms of erythropoietin?
No. It specifically covers genetically engineered erythropoietin with certain glycosylation modifications and related production methods.
2. Can biosimilar companies produce EPO now that the patent has expired?
Yes. The expiration allows biosimilar manufacturers to develop and sell generic versions of EPO without infringing this patent, though other patents may still apply.
3. Are there ongoing patents that extend the protection around genetically engineered EPO?
Yes. Companies are pursuing patents on improved glycoengineering, newer cell lines, and production methods, which can extend exclusivity.
4. How has patent litigation affected the EPO biosimilar market?
Legal battles have delayed some biosimilar entries; however, the core patent expiration greatly facilitates market entry.
5. What strategies do innovator companies use to extend patent protection for EPO products?
Companies develop new modifications, seek patent extensions, and file method-of-use or formulation patents to prolong market exclusivity.
[1] Source: court case records, patent office databases, and legal analyses of Amgen’s patent portfolio.
More… ↓
⤷ Start Trial
|
